In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dexcom Inc.

www.dexcom.com

Latest From Dexcom Inc.

Dexcom Stocks Continue To Drop After Short-Seller Warns of Competition From Abbott

Investment managing firm Spruce Point says factors such as patients hacking their older Dexcom continuous glucose meters, the company’s decision to not disclose its patient base and competition from Abbott’s upcoming Libre 2 CGMs are red flags that Dexcom is overstating its market potential. Dexcom's stocks lost a fifth of their value after the short-seller released a recent report that says the firm is overvalued.

Market Access Pricing Strategies

2018 US Device Approvals: The Year Of De Novos And Digital Health

It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.

Approvals FDA

Market Intel: Managing Diabetes With Digital Apps: Physicians' Views On Pros And Cons

With a growing number of diabetes apps on the market, patients and physicians can obtain a large amount of data to help manage the disease. In this second part of a two-part series on the blood glucose monitoring devices market, two endocrinologists express their views on the considerations and pitfalls of using apps to help manage diabetes, and they recommend specific apps.

Diabetic Care Digital Health

Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes-Monitoring Market

The global blood glucose monitoring devices market is expected to exceed $7bn by 2022, driven by the smaller, but fastest-growing continuous glucose monitoring (CGM) segment, which is expanding at double-digits. The much bigger blood glucose meter (BGM) segment, meanwhile, is facing increased competition from lower-cost manufacturers, innovative startups and tech giants like Apple that are attracting consumers with smart devices and packaged diabetes management solutions. This first of a two-part series looks more closely at the competitive landscape of the two major product segments – BGM and CGM – with insights from endocrinologists. The second part will focus on the pros and cons of using diabetes management apps and highlights the best diabetes apps.

Diabetic Care Digital Health
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dexcom Inc.
  • Senior Management
  • Kevin Sayer, Pres. & CEO
    Jess Roper, SVP, CFO
    Richard B Doubleday, Chief Commercial Officer
    Jacob Leach, SVP, R&D
    Steven Pacelli, EVP, Strategy & Corp. Dev.
  • Contact Info
  • Dexcom Inc.
    Phone: (858) 200-0200
    6340 Sequence Dr.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register